Immune Checkpoint Inhibitors - Global Strategic Business Report

Report
194 Pages
April 2024
Region: Global
Global Industry Analysts, Inc
ID: 5309487

The global market for Immune Checkpoint Inhibitors is estimated at US$63.9 Billion in 2023 and is projected to reach US$185.4 Billion by 2030, growing at a CAGR of 16.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the PD-1 Inhibitors segment, which is expected to reach US$97.8 Billion by 2030 with a CAGR of a 16.1%. The PD-L1 Inhibitors segment is also set to grow at 17% CAGR over the next 7 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $19.6 Billion in 2023, and China, forecasted to grow at an impressive 15.5% CAGR to reach $31.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Immune Checkpoint Inhibitors Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Immune Checkpoint Inhibitors Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Immune Checkpoint Inhibitors Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 42 Featured):

AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
Fortress Biotech, Inc.
Immutep Ltd.
Merck & Co., Inc.
Merck KGaA
Novartis International AG
Pfizer, Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
Immune Checkpoint Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 2: World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 3: World Recent Past, Current & Future Analysis for Bladder cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 4: World 7-Year Perspective for Bladder cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 6: World 7-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 7: World Recent Past, Current & Future Analysis for Hodgkin lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 8: World 7-Year Perspective for Hodgkin lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 9: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 10: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 11: World Immune Checkpoint Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 12: World Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 13: World 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for PD-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 15: World 7-Year Perspective for PD-1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 16: World Recent Past, Current & Future Analysis for PD-L1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 17: World 7-Year Perspective for PD-L1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 18: World Recent Past, Current & Future Analysis for CLTA-4 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 19: World 7-Year Perspective for CLTA-4 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 20: USA Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 21: USA 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 22: USA Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 23: USA 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

CANADA

Table 24: Canada Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 25: Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 26: Canada Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 27: Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

JAPAN

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 28: Japan Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 29: Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 30: Japan Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 31: Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

CHINA

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 32: China Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 33: China 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 34: China Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 35: China 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

EUROPE

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 36: Europe Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 37: Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 38: Europe Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 39: Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
Table 40: Europe Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 41: Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

FRANCE

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 42: France Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 43: France 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 44: France Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: France 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

GERMANY

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 46: Germany Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 47: Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 48: Germany Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 49: Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

ITALY

Table 50: Italy Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 52: Italy Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 53: Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

UNITED KINGDOM

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 54: UK Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 55: UK 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 56: UK Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 57: UK 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

REST OF EUROPE

Table 58: Rest of Europe Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 59: Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 60: Rest of Europe Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 61: Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

ASIA-PACIFIC

Immune Checkpoint Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 63: Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 64: Asia-Pacific Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 65: Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

REST OF WORLD

Table 66: Rest of World Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 67: Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2024 & 2030
Table 68: Rest of World Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Type - PD-1, PD-L1 and CLTA-4 - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 69: Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Type - Percentage Breakdown of Value Sales for PD-1, PD-L1 and CLTA-4 for the Years 2024 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
Fortress Biotech, Inc.
Immutep Ltd.
Merck & Co., Inc.
Merck KGaA
Novartis International AG
Pfizer, Inc.

Table Information

Report Attribute	Details
No. of Pages	194
Published	April 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 63.9 Billion
Forecasted Market Value ( USD ) by 2030	$ 185.4 Billion
Compound Annual Growth Rate	16.4%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4783EUR$4,950USD£4,038GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9088EUR$9,405USD£7,672GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€14349EUR$14,850USD£12,114GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 42 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Global Immune Checkpoint Inhibitors Market Report and Forecast 2024-2032

Checkpoint Inhibitor Refractory Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2024-2032

Immune Checkpoint Inhibitors Market By Type, By Application: Global Opportunity Analysis and Industry Forecast, 2023-2032

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024